Clinical Trials Logo

Thromboangiitis Obliterans clinical trials

View clinical trials related to Thromboangiitis Obliterans.

Filter by:

NCT ID: NCT05854615 Recruiting - Clinical trials for Critical Limb Ischemia

Efficacy and Safety of Stempeucel® in Patients With Critical Limb Ischemia (CLI) Due to Buerger's Disease

Start date: January 1, 2024
Phase: Phase 4
Study type: Interventional

The goal of this observational, practice-based feasibility study is to observe the efficacy and safety of intramuscular administration of Stempeucel® in Malaysian patients with critical limb ischemia (CLI) due to Buerger's disease. The main questions it aims to answer are: - Can intramuscular administration of Stempeucel® reduce symptoms of CLI due to Buerger's disease while improving the healing rate and functional outcomes? - Does intramuscular administration of Stempeucel® causes any serious adverse events in CLI due to Buerger's disease patients? Study patients will be assessed by the PI before administering the Stempeucel® for any other organ with inflammation. The study patients will also be followed up to the duration of 1 year after study treatment administration for safety and efficacy assessment.

NCT ID: NCT05698979 Not yet recruiting - Raynaud Syndrome Clinical Trials

Evaluation of Botulinum TOXin Type A in the Treatment of Buerger's Disease

BETOX
Start date: August 30, 2023
Phase: Phase 3
Study type: Interventional

The main objective is to assess the feasibility of treatment by injecting botulinum toxin A into the hand or foot of patients with signs of critical ischemia secondary to Buerger's disease. The injection of botulinum toxin A is carried out at the end of a single session during an hospitalization. Furthermore, tolerance and effects on the disease are evaluated at 1, 3 and 6 months post injections.

NCT ID: NCT04914247 Available - Non-healing Wound Clinical Trials

Individual Patient Expanded Access IND for Selexipag (Uptravi) in Participants With Non-healing Wound, Buerger's Disease

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this expanded access program (EAP) is to provide Selexipag (Uptravi) for the treatment of participant with non-healing wound, buerger's disease.

NCT ID: NCT04746599 Recruiting - Diabetic Foot Clinical Trials

Autologous Fat Grafting in the Treatment of Critical Limb Ischaemia

Start date: January 1, 2021
Phase: N/A
Study type: Interventional

Critical Limb Ischaemia (CLI) is a condition characterized by chronic ischemic at-rest pain, ulcers, or gangrene for more than 2 weeks in one or both legs, attributable to objectively proven arterial occlusive disease.CLI is associated with a high risk of lower amputation, diminished quality of life and mortality. Revascularization by either bypass surgery or endovascular recanalization is considered the first-choice treatment in patients with CLI. Revascularization is not always possible because patients with CLI often have severe comorbidities or because it is not technically feasible. On the basis of their well-recognized regenerative and angiogenetic properties, cell therapy with autologous bone marrow-derived mesenchymal stem cells (BMMSCs) has been proposed and tested in different animal models and in some human pathological conditions characterized by peripheral ischemia and wound formation.

NCT ID: NCT03056742 Withdrawn - Clinical trials for Critical Limb Ischemia Due to Buerger's Disease

A Clinical Trial to Study the Efficacy and Safety of Stempeucel® in Patients With CLI Due to Buergers Disease

Start date: February 20, 2017
Phase: Phase 2
Study type: Interventional

This study is being conducted as an extension of the phase II clinical trial SRPL/CLI/10-11/001 (NCT01484574). The CDSCO has recommended flexibility for continued clinical study in consultation with ICMR, as per recommendation of Cellular biology based therapeutic drug evaluation committee (CBBTDEC).

NCT ID: NCT02864654 Enrolling by invitation - Clinical trials for Peripheral Arterial Disease

Effectiveness and Safety of Adipose-Derived Regenerative Cells for the Treatment of Critical Lower Limb Ischemia

Start date: July 2016
Phase: Phase 1/Phase 2
Study type: Interventional

Adipose-derived regenerative cells (ADRC) will be extracted from lipoaspirate by enzymatic digestion. 10 mL of autologous ADRC suspension injected intramuscularly, close to the site of muscle injury. All patients will receive cell therapy. This is a single arm study with no control.

NCT ID: NCT02501018 Completed - Clinical trials for Critical Limb Ischemia

Study to Assess the Efficacy and Safety of CLBS12 in Patients With Critical Limb Ischemia (CLI)

Start date: November 1, 2017
Phase: Phase 2
Study type: Interventional

A prospective, open label, controlled, randomized, double arm, multi-center study to assess the efficacy and safety of CLBS12 in patients with critical limb ischemia (CLI) due to arteriosclerosis obliterans (ASO) with a single arm sub-study to assess the safety and potential efficacy of CLBS12 in patients with CLI due to Buerger's Disease (BD).

NCT ID: NCT02128750 Completed - Ischemia Clinical Trials

Contrast Enhanced Ultrasound and Muscle

Echomuscle
Start date: February 2011
Phase: N/A
Study type: Interventional

The primary objective of our work is to show that quantification of muscular microvascularisation evaluated by injection of contrast agent is different between chronic critical limb ischemia (before revascularization) and after (healing of ischemia) and thus make the proof of its utility in evaluation of PAD therapeutics.

NCT ID: NCT02089828 Recruiting - Clinical trials for Peripheral Arterial Disease

Purified CD34+ Cells Versus Peripheral Blood Mononuclear Cells in Treatment of Critical Limb Ischemia

Start date: March 2014
Phase: N/A
Study type: Interventional

To compare the efficacy and cost-effectiveness between purified CD34+ cells and peripheral blood mononuclear cells in treatment of critical limb ischemia

NCT ID: NCT01484574 Completed - Clinical trials for Critical Limb Ischemia

A Clinical Trial to Study the Efficacy and Safety of Different Doses of Bone Marrow Derived Mesenchymal Stem Cells in Patients With Critical Limb Ischemia Due to Buergers Disease

Start date: January 2012
Phase: Phase 2
Study type: Interventional

This is an open label, non-randomized, dose ranging study to evaluate the safety and efficacy of different doses of Stempeucel in critical limb ischemia patients.